Telix and Invicro Advance AI Partnership

Melbourne (Australia) and Boston, MA (U.S.A.) – June 14, 2022. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to develop an artificial intelligence (AI) platform to accompany Telix’s PSMA-PET imaging agent, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide) – known as TelixAI™.

TelixAI™ seeks to increase the efficiency and reproducibility of clinicians’ imaging assessments using advanced analysis capabilities with an initial focus on prostate cancer. The platform is designed to do this by automatically separating healthy versus abnormal tracer uptake and then classifies lesions as either visceral (soft tissue) or bone lesions.